Periodic mobile application (eMOM) with self-tracking of glucose and lifestyle improves treatment of diet-controlled gestational diabetes without human guidance : a randomized controlled trial

Mikko Kytö*, Shinji Hotta, Sari Niinistö, Pekka Marttinen, Tuuli E. Korhonen, Lisa T. Markussen, Giulio Jacucci, Harri Sievänen, Henri Vähä-Ypyä, Ilkka Korhonen, Suvi Virtanen, Seppo Heihonen, Saila B. Koivusalo

*Tämän työn vastaava kirjoittaja

Tutkimustuotos: LehtiartikkeliArticleScientificvertaisarvioitu

Abstrakti

Background: Digitalization with minimal human resources could support self-management among women with gestational diabetes and improve maternal and neonatal outcomes. Objective: This study aimed to investigate if a periodic mobile application (eMOM) with wearable sensors improves maternal and neonatal outcomes among women with diet-controlled gestational diabetes without additional guidance from healthcare personnel. Study Design: Women with gestational diabetes were randomly assigned in a 1:1 ratio at 24 to 28 weeks’ gestation to the intervention or the control arm. The intervention arm received standard care in combination with use of the periodic eMOM, whereas the control arm received only standard care. The intervention arm used eMOM with a continuous glucose monitor, an activity tracker, and a food diary 1 week/month until delivery. The primary outcome was the change in fasting plasma glucose from baseline to 35 to 37 weeks’ gestation. Secondary outcomes included capillary glucose, weight gain, nutrition, physical activity, pregnancy complications, and neonatal outcomes, such as macrosomia. Results: In total, 148 women (76 in the intervention arm, 72 in the control arm; average age, 34.1±4.0 years; body mass index, 27.1±5.0 kg/m2) were randomized. The intervention arm showed a lower mean change in fasting plasma glucose than the control arm (difference, −0.15 mmol/L vs −2.7 mg/mL; P=.022) and lower capillary fasting glucose levels (difference, −0.04 mmol/L vs −0.7 mg/mL; P=.002). The intervention arm also increased their intake of vegetables (difference, 11.8 g/MJ; P=.043), decreased their sedentary behavior (difference, −27.3 min/d; P=.043), and increased light physical activity (difference, 22.8 min/d; P=.009) when compared with the control arm. In addition, gestational weight gain was lower (difference, −1.3 kg; P=.015), and there were less newborns with macrosomia in the intervention arm (difference, −13.1 %; P=.036). Adherence to eMOM was high (daily use >90%), and the usage correlated with lower maternal fasting (P=.0006) and postprandial glucose levels (P=.017), weight gain (P=.028), intake of energy (P=.021) and carbohydrates (P=.003), and longer duration of the daily physical activity (P=.0006). There were no significant between-arm differences in terms of pregnancy complications. Conclusion: Self-tracking of lifestyle factors and glucose levels without additional guidance improves self-management and the treatment of gestational diabetes, which also benefits newborns. The results of this study support the use of digital self-management and education tools in maternity care.

AlkuperäiskieliEnglanti
JulkaisuAmerican Journal of Obstetrics and Gynecology
DOI - pysyväislinkit
TilaSähköinen julkaisu (e-pub) ennen painettua julkistusta - 1 maalisk. 2024
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Sormenjälki

Sukella tutkimusaiheisiin 'Periodic mobile application (eMOM) with self-tracking of glucose and lifestyle improves treatment of diet-controlled gestational diabetes without human guidance : a randomized controlled trial'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä